Efficacy and safety of nimotuzumab in addition to radiotherapy and temozolomide for cerebral glioblastoma: a phase II multicenter clinical trial

Background: Nimotuzumab is a humanized anti-epidermal growth factor receptor (EGFR) antibody that has shown preclinical and clinical anticancer activity in cerebral glioblastoma multiforme (GBM). We conducted a phase II, single-arm, multicenter clinical trial to evaluate the benefit of adding nimotu...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Xiao-Jing, Li, Xian-Ming, Cai, Lin-Bo, Sun, Jian-Cong, Wang, Si-Yang, Wang, Xi-Cheng, Pang, Xiao-Lin, Deng, Mei-Ling, Chen, Fang-Fang, Wang, Zhi-Qiang, Chen, Fu-Rong, Zhang, Hong-Hong, Wang, Hui-Yun, Piedra, Patricia, Chen, Zhong-Ping, Lin, Jun, Wu, Shao-Xiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603389/
https://www.ncbi.nlm.nih.gov/pubmed/31289592
http://dx.doi.org/10.7150/jca.30123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603389/
https://www.ncbi.nlm.nih.gov/pubmed/31289592
http://dx.doi.org/10.7150/jca.30123

Ejemplares similares